EU must act to save its minor markets for medicines
This article was originally published in Scrip
Executive Summary
The fact that many poor countries globally suffer as a result of the lack of access to life-saving medicines is lamentable. Whereas certain mechanisms have been devised with the aim of addressing this issue, the move towards assuring worldwide access is far from complete. But whilst the paucity of medicines in the developing world is a stain on the conscience of richer countries and the pharmaceutical industry, the unavailability of drugs in EU member states – many of which host flourishing drug manufacturers – is shocking.